• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Medical Physics >Recommendations of the American Association of Physicists in Medicine regarding the impact of implementing the 2004 task group 43 report on dose specification for 103Pd and 125I interstitial brachytherapy.
【24h】

Recommendations of the American Association of Physicists in Medicine regarding the impact of implementing the 2004 task group 43 report on dose specification for 103Pd and 125I interstitial brachytherapy.

机译：美国医师协会协会关于实施2004年任务组43报告对103Pd和125I间质近距离放射治疗剂量规范的影响的建议。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In March 2004, the recommendations of the American Association of Physicists in Medicine (AAPM) on the interstitial brachytherapy dosimetry using 125I and 103Pd were reported in Medical Physics [TG-43 Update: Rivard et al., 31, 633-674 (2004)]. These recommendations include some minor changes in the dose-calculation formalism and a major update of the dosimetry parameters for eight widely used interstitial brachytherapy sources. A full implementation of these recommendations could result in unintended changes in delivered dose without corresponding revisions in the prescribed dose. Because most published clinical experience with permanent brachytherapy is based upon two widely used source models, the 125I Model 6711 and 103Pd Model 200 sources, in this report we present an analysis of the dosimetric impact of the 2004 TG-43 dosimetry parameters on the history of dose delivery for these two source models. Our analysis indicates that the currently recommended prescribed dose of 125 Gy for Model 200 103Pdimplants planned using previously recommended dosimetry parameters [AAPM 103Pd dose prescription: Williamson et al., Med. Phys. 27, 634-642 (2000)] results in a delivered dose of 120 Gy according to dose calculations based on the 2004 TG-43 update. Further, delivered doses prior to October 1997 varied from 113 to 119 Gy for a prescribed dose of 115 Gy compared to 124 Gy estimated by the AAPM 2000 report. For 125I implants using Model 6711 seeds, there are no significant changes (less than 2%). Practicing physicians should take these results into account when selecting the clinically appropriate prescribed dose for 103Pd interstitial implant patients following implementation of the 2004 TG-43 update dose-calculation recommendations. The AAPM recommends that the radiation oncology community review this report and consider whether the currently recommended dose level (125 Gy) needs to be revised.
机译：2004年3月，《医学物理学》杂志报道了美国医学物理学会（AAPM）关于使用125I和103Pd进行间质近距离放射治疗剂量学的建议[TG-43更新：Rivard等，31，633-674（2004） ]。这些建议包括剂量计算形式上的一些细微变化，以及八种广泛使用的间质性近距离放射治疗源的剂量学参数的重大更新。完全执行这些建议可能会导致输送剂量意外变化，而未对规定剂量进行相应修改。由于大多数关于永久性近距离放射疗法的临床经验都是基于两种广泛使用的来源模型，即125I模型6711和103Pd模型200来源，因此在本报告中，我们对2004 TG-43剂量参数对剂量史的剂量学影响进行了分析。这两个来源模型的剂量传递。我们的分析表明，使用先前推荐的剂量学参数[AAPM 103Pd剂量处方：Williamson等，Med。物理27，634-642（2000）]根据2004 TG-43更新的剂量计算得出120 Gy的输送剂量。此外，1997年10月之前的规定剂量115 Gy的输送剂量从113 Gy到119 Gy，而AAPM 2000报告估计为124 Gy。对于使用6711型种子的125I植入物，没有显着变化（小于2％）。在执行2004 TG-43更新剂量计算建议后，为103Pd间质植入物患者选择临床上合适的处方剂量时，执业医师应考虑这些结果。 AAPM建议放射肿瘤学界审查此报告，并考虑是否需要修改当前建议的剂量水平（125 Gy）。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号